Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404697 | 0.81 | GNAI3 (0.39) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL2399298 | 0.79 | RAB9A (0.56) | L3MBTL1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2584142 | 0.74 | MAPT (0.49) | MEN1KMT2APOLBGPR119LMNA | |
| SCHEMBL2400865 | 0.73 | GAA (0.40) | TDP1POLBALDH1A1LMNAMAPT | |
| SCHEMBL2400758 | 0.72 | SLC6A7 (0.44) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL22057286 | 0.72 | GPR119 (0.35) | KMT2AGPR119 | |
| SCHEMBL2400919 | 0.71 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1LMNA | |
| SCHEMBL22417656 | 0.71 | RAB9A (0.41) | L3MBTL1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2404903 | 0.71 | GRM5 (0.52) | ALDH1A1 | |
| SCHEMBL20743778 | 0.69 | NPC1 (0.39) | L3MBTL1GNAI3GNAI1GNAO1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557796-B2 | Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | L3MBTL1 4865/4885MEN1 2995/4885KMT2A 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.